Novo Nordisk’s Alzheimer’s study falls short, marking a setback for the pharmaceutical leader.
Novo Nordisk (NOVOb.CO) reported on Monday that the closely watched Alzheimer’s trials using an older oral version of semaglutide had failed to show any meaningful effect in slowing down the progression of the disease.
